Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Laboratory Corporation of America Holdings Stock Research

LH

205.14USD-0.06(-0.03%)Market Closed
Watchlist

Market Summary

USD205.14-0.06
Market Closed
-0.03%

LH Alerts

  • Big fall in earnings (Y/Y)

LH Stock Price

LH RSI Chart

LH Valuation

Market Cap

18.2B

Price/Earnings (Trailing)

21.91

Price/Sales (Trailing)

1.29

Price/Free Cashflow

16.79

LH Price/Sales (Trailing)

LH Profitability

Operating Margin

27.97%

Return on Equity

9.67%

Return on Assets

4.95%

Free Cashflow Yield

5.96%

LH Fundamentals

LH Revenue

Revenue (TTM)

14.1B

Revenue Y/Y

3.79%

Revenue Q/Q

-19.7%

LH Earnings

Earnings (TTM)

830.7M

Earnings Y/Y

-47.32%

Earnings Q/Q

-11.27%

Price Action

52 Week Range

198.69258.90
(Low)(High)

Last 7 days

0.3%

Last 30 days

-4.8%

Last 90 days

-12.6%

Trailing 12 Months

-6.5%

LH Financial Health

Current Ratio

1.63

LH Investor Care

Buy Backs (1Y)

16.18%

Diluted EPS (TTM)

10.04

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for LH

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-08-08
ANDERSON KERRII B
sold
-1,057,830
211
-5,000
-
2023-08-01
Wilkinson Peter J
sold (taxes)
-3,631
213
-17.00
svp, chief accounting officer
2023-08-01
Wilkinson Peter J
acquired
-
-
56.00
svp, chief accounting officer
2023-06-29
van der Vaart Sandra D
sold
-50,880
240
-212
evp, chief legal officer
2023-05-19
Kirchgraber Paul R
sold
-932,707
216
-4,300
ceo, covance drug development
2023-05-19
Kirchgraber Paul R
acquired
784,793
182
4,300
ceo, covance drug development
2023-05-18
Schroeder Mark S
acquired
195,900
130
1,500
evp, pres diagnostics & coo
2023-05-18
Schroeder Mark S
sold
-325,155
216
-1,500
evp, pres diagnostics & coo
2023-03-31
Schroeder Mark S
sold
-879,982
225
-3,897
evp, president-diagnostics lab
2023-03-30
Wilkinson Peter J
acquired
-
-
1,798
svp, chief accounting officer

1–10 of 50

Which funds bought or sold LH recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-20
Mondrian Investment Partners LTD
added
5.92
16,211,300
158,182,000
3.16%
2023-09-18
WASHINGTON CAPITAL MANAGEMENT, INC
added
113
672,340
1,211,480
1.03%
2023-09-12
Farther Finance Advisors, LLC
added
31.5
22,355
80,638
0.02%
2023-09-08
TUCKER ASSET MANAGEMENT LLC
reduced
-74.19
-5,181
1,931
-%
2023-09-07
JAG CAPITAL MANAGEMENT, LLC
added
36.7
760,562
2,497,040
0.29%
2023-09-07
ST GERMAIN D J CO INC
new
-
43,439
43,439
-%
2023-09-05
Covenant Partners, LLC
unchanged
-
14,030
284,287
0.10%
2023-08-25
EUBEL BRADY & SUTTMAN ASSET MANAGEMENT INC
added
2.18
1,015,000
14,568,000
2.01%
2023-08-24
Alberta Investment Management Corp
added
33.68
177,080
612,978
0.01%
2023-08-23
Rehmann Capital Advisory Group
reduced
-0.47
57,198
1,278,620
0.12%

1–10 of 48

Latest Funds Activity

Are funds buying LH calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own LH
No. of Funds

Schedule 13G FIlings of Laboratory Corporation of America Holdin

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
11.79%
10,450,115
SC 13G/A
Jan 26, 2023
blackrock inc.
13.0%
11,474,507
SC 13G/A
Jan 20, 2023
blackrock inc.
13.0%
11,474,507
SC 13G/A
Mar 09, 2022
blackrock inc.
10.4%
9,706,541
SC 13G/A
Feb 10, 2022
vanguard group inc
11.24%
10,753,065
SC 13G/A
Feb 01, 2022
blackrock inc.
8.6%
8,274,411
SC 13G/A
Feb 10, 2021
vanguard group inc
10.68%
10,405,602
SC 13G/A
Jan 29, 2021
blackrock inc.
8.0%
7,832,565
SC 13G/A
Feb 12, 2020
vanguard group inc
11.21%
10,891,852
SC 13G/A
Feb 05, 2020
blackrock inc.
9.1%
8,855,703
SC 13G/A

Recent SEC filings of Laboratory Corporation of America Holdin

View All Filings
Date Filed Form Type Document
Sep 14, 2023
8-K
Current Report
Sep 11, 2023
8-K
Current Report
Aug 10, 2023
4
Insider Trading
Aug 09, 2023
8-K
Current Report
Aug 08, 2023
144
Notice of Insider Sale Intent
Aug 04, 2023
10-Q
Quarterly Report
Aug 03, 2023
4
Insider Trading
Jul 31, 2023
8-K
Current Report
Jul 27, 2023
8-K
Current Report
Jul 24, 2023
SC 13D/A
13D - Major Acquisition

LH Fair Value

Loading...

Peers (Alternatives to Laboratory Corporation of America Holdin)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
69.4B
61.9B
-7.50% 26.00%
12.02
1.12
3.02% -11.37%
18.2B
14.1B
-4.84% -6.54%
21.91
1.29
-5.68% -58.27%
14.0B
9.5B
-5.93% 1.08%
17.63
1.48
-10.34% -46.50%
MID-CAP
9.4B
11.7B
1.41% 13.03%
20.16
0.8
0.96% -43.93%
7.8B
2.2B
2.63% 10.06%
34.39
3.56
2.13% -18.31%
7.1B
19.9B
-2.85% 22.41%
6.26
0.36
3.98% -22.32%
7.0B
4.6B
-0.06% 39.84%
22.16
1.52
9.56% -4.24%
6.5B
2.8B
-6.23% -13.68%
23.9
2.33
13.40% -2.45%
3.3B
957.5M
-8.01% -15.46%
66.71
3.43
55.17% 8.05%
3.2B
510.2M
-27.36% -50.73%
-6.35
6.32
25.00% 4.56%
SMALL-CAP
1.9B
1.5B
-8.12% 43.46%
-147.16
1.24
12.20% -155.34%
39.3M
52.9M
-8.98% -46.92%
-1.12
0.74
23.27% 10.26%
15.5M
20.4M
-11.49% -6.52%
28.15
0.76
9.05% -51.79%
4.7M
10.8M
-41.82% -73.41%
-0.13
0.43
-71.53% 35.85%

Laboratory Corporation of America Holdin News

Returns for LH

Cumulative Returns on LH

7.6%


10-Year Cumulative Returns

6.1%


7-Year Cumulative Returns

3.8%


5-Year Cumulative Returns

4.1%


3-Year Cumulative Returns

Risks for LH

What is the probability of a big loss on LH?

66.5%


Probability that Laboratory Corporation of America Holdin stock will be more than 20% underwater in next one year

37.7%


Probability that Laboratory Corporation of America Holdin stock will be more than 30% underwater in next one year.

19.2%


Probability that Laboratory Corporation of America Holdin stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does LH drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Laboratory Corporation of America Holdin was unfortunately bought at previous high price.

Drawdowns

Financials for Laboratory Corporation of America Holdin

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue0.8%14,09213,98114,87714,48514,94115,85916,12116,55516,38815,31613,97912,44211,47511,58711,55511,38911,29211,27611,33311,29111,081
Cost Of Revenue2.1%10,24610,03510,4929,87510,00510,60110,49710,40010,0609,4929,0268,5748,3488,3978,3028,1858,1158,0898,1578,0707,865
Gross Profit-2.5%3,8463,9474,3854,6104,9365,2585,6246,1546,3285,8244,9533,8693,1273,1913,2533,2043,1773,1873,1763,2213,215
  S&GA Expenses3.6%2,1062,0331,9971,9501,9601,9861,9521,9261,8261,7641,7291,6251,6071,6261,6251,6081,5881,5681,5711,5911,591
Interest Expenses4.0%196189180174170206212217227201207224233239241235233237244254254
Net Income-17.0%8311,0001,2791,7561,9912,0992,3772,7632,8792,6431,556845-175-2162862178538968841,4141,266
Net Income Margin-100.0%-0.07*0.09*0.12*0.13*0.13*0.15*0.17*0.18*0.17*0.11*0.07*0.03*0.03*0.07*------
Free Cashflow-100.0%-1,2631,4741,4861,8651,7042,7772,7772,8362,7191,7541,5201,1741,0701,045------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets-12.3%17,71920,20020,15519,82620,40320,72820,38520,86720,41720,41720,07218,74017,84917,29818,04617,84817,74416,97116,18516,66116,505
  Current Assets9.1%5,1214,6954,6254,3725,0315,2305,3316,0215,6945,6385,1254,0863,4132,8912,9812,9882,8492,8852,8353,2743,021
    Cash Equivalents390.1%1,9313943214109781,2341,4732,0371,9631,8911,321667557324338361265349427893893
  Inventory1.3%488481471468436441401411421428423393342254245235220234237233231
  Net PPE-6.2%2,7622,9442,7942,8852,8702,8082,8152,6922,7022,6972,7302,6092,6282,6102,6372,4632,5442,4581,7401,7341,711
  Goodwill-23.8%6,1828,1166,1248,2188,1148,1667,9597,9077,7457,7217,7527,6147,4237,3897,8657,8157,8447,3867,3607,3637,423
Liabilities-9.4%8,9149,83910,0409,7159,9829,98710,09110,32110,15110,37510,61410,48110,47710,26010,45910,59710,5809,8409,1959,3939,447
  Current Liabilities-24.3%2,1832,8863,0792,5222,6432,6422,7832,8882,6673,3693,0793,0103,0342,4582,6562,5552,4962,5271,8792,1062,122
    LT Debt, Non Current-0.2%5,0425,0525,0395,3345,3605,3835,4175,4175,4234,9215,4195,4175,4175,7905,7906,1016,1355,4965,9916,0456,039
Shareholder's Equity-15.1%8,78510,34210,09710,09210,40110,72110,27310,60110,32210,0989,4378,2397,3537,0207,6447,0207,1447,1117,0487,2487,038
  Retained Earnings-17.6%8,83610,73010,58210,84510,89810,94810,45710,78710,41710,1729,4798,4647,7617,5297,9817,6777,4567,2657,1576,9226,603
  Additional Paid-In Capital97.9%94.0048.00---29.00---67.0011081.0032.00-27.0048.0091.001,4011,4511,8281,935
Shares Outstanding-13.9%89.0010388.00104106111108111112114113113113113113113114115115118119
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations-12.8%1,5001,7211,9562,0002,3932,3083,1103,1873,2063,0892,1351,9311,6001,4831,4451,3611,1581,2921,3051,3841,529
  Share Based Compensation0.8%14814714415616516315413810712311210811399.0010710492.0091.0092.0095.00109
Cashflow From Investing-0.9%-1,189-1,178-1,652-1,633-1,477-1,325-884-758-636-669-643-667-621-1,249-1,283-1,277-488141207175-1,688
Cashflow From Financing148.3%660-1,365-1,322-1,958-1,787-1,633-2,065-1,058-1,173-864-517-965-684-252-252-606-620-1,428-1,389-1,06780.00
  Dividend Payments-1.1%259261-17589.00----------------
  Buy Backs-2,200-1,1001,600933800-669437137100219250450450800850725700340232

LH Income Statement

2023-06-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
$ in Millions
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Net restructuring and other special charges$ 15.8$ 31.5$ 23.3$ 35.0
Operating Income (Loss)266.3428.8596.11,034.0
Interest Expense49.842.3100.584.4
Equity method income, net0.91.4(1.2)4.8
Investment income4.51.76.72.5
Other, net(16.9)(29.5)(23.8)(45.2)
Earnings before income taxes205.0360.1477.3911.7
Provision for income taxes49.892.1113.7222.6
Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest155.2268.0363.6689.1
Net earnings189.1358.9402.4851.0
Net Income (Loss) Attributable to Noncontrolling Interest0.20.30.60.8
Net Income (Loss) Attributable to Parent$ 188.9$ 358.6$ 401.8$ 850.2
Income (Loss) from Continuing Operations, Per Basic Share$ 1.75$ 2.90$ 4.10$ 7.43
Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share0.380.990.431.74
Basic earnings per common share (in dollars per share)2.133.894.539.17
Diluted earnings per common share (in dollars per share)$ 2.12$ 3.87$ 4.51$ 9.11
Revenues$ 3,033.7$ 2,923.0$ 6,071.5$ 6,067.5
Cost of Revenue2,191.51,980.54,379.24,042.9
Gross Profit842.2942.51,692.32,024.6
Selling, general and administrative expenses505.8432.4963.0854.4
Amortization of intangibles and other assets51.549.8104.9100.0
Asset Impairment Charges2.80.05.01.2
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest$ 33.9$ 90.9$ 38.8$ 161.9
Income (Loss) from Continuing Operations, Per Diluted Share$ 1.74$ 2.89$ 4.08$ 7.38
Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share$ 0.38$ 0.98$ 0.43$ 1.73
Revenues$ 3,033.7$ 2,923.0$ 6,071.5$ 6,067.5
Cost of Revenue2,191.51,980.54,379.24,042.9
Gross Profit842.2942.51,692.32,024.6
Selling, general and administrative expenses505.8432.4963.0854.4
Amortization of intangibles and other assets51.549.8104.9100.0
Asset Impairment Charges2.80.05.01.2
Net restructuring and other special charges15.831.523.335.0
Operating Income (Loss)266.3428.8596.11,034.0
Other income (expenses):    
Interest expense(49.8)(42.3)(100.5)(84.4)
Equity method income, net0.91.4(1.2)4.8
Investment income4.51.76.72.5
Other, net(16.9)(29.5)(23.8)(45.2)
Earnings before income taxes205.0360.1477.3911.7
Provision for income taxes49.892.1113.7222.6
Net earnings189.1358.9402.4851.0
Less: Net earnings attributable to the noncontrolling interest(0.2)(0.3)(0.6)(0.8)
Net earnings attributable to Laboratory Corporation of America Holdings$ 188.9$ 358.6$ 401.8$ 850.2
Basic earnings per common share (in dollars per share)$ 2.13$ 3.89$ 4.53$ 9.17
Diluted earnings per common share (in dollars per share)$ 2.12$ 3.87$ 4.51$ 9.11

LH Balance Sheet

2023-06-30
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)
3 Months Ended6 Months Ended
Jun. 30, 2023
USD ($)
Jun. 30, 2023
USD ($)
Dec. 31, 2022
USD ($)
Current assets:   
Accounts Receivable, after Allowance for Credit Loss, Current$ 1,904,800,000$ 1,904,800,000$ 1,785,500,000
Unbilled Contracts Receivable137,800,000137,800,000211,800,000
Supplies inventories487,800,000487,800,000470,600,000
Prepaid expenses and other659,900,000659,900,000610,400,000
Disposal Group, Including Discontinued Operation, Assets, Current001,226,100,000
Total current assets5,120,900,0005,120,900,0004,625,000,000
Property, plant and equipment, net2,762,100,0002,762,100,0002,794,100,000
Goodwill, net6,182,200,0006,182,200,0006,123,700,000
Intangible Assets, Net (Excluding Goodwill)3,154,100,0003,154,100,0003,123,600,000
Joint venture partnerships and equity method investments67,200,00067,200,00065,700,000
Deferred Income Taxes and Other Assets, Current6,400,0006,400,0006,400,000
Other assets, net425,800,000425,800,000378,400,000
Disposal Group, Including Discontinued Operation, Assets, Noncurrent003,038,200,000
Total assets17,718,700,00017,718,700,00020,155,100,000
Liabilities, Current [Abstract]   
Accounts Payable, Current713,100,000713,100,000852,200,000
Accrued Liabilities, Current657,800,000657,800,000787,000,000.0
Deferred Revenue, Current349,700,000349,700,000310,600,000
Operating Lease, Liability, Current154,800,000154,800,000163,800,000
Finance Lease, Liability, Current6,500,0006,500,0006,000,000.0
Current debt excluding finance lease liability301,400,000301,400,000301,300,000
Long-term debt, less current portion2,183,300,0002,183,300,0003,078,500,000
Long-term Debt, Excluding Current Maturities5,042,400,0005,042,400,0005,038,800,000
Commitments and contingent liabilities418,500,000418,500,000401,100,000
Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent00241,300,000
Operating Lease, Liability, Noncurrent623,500,000623,500,000652,900,000
Finance Lease, Liability, Noncurrent81,700,00081,700,00083,600,000
Deferred income taxes and other tax liabilities564,500,000564,500,000543,400,000
Noncontrolling interest8,913,900,0008,913,900,00010,039,600,000
Shareholders' equity:   
Common stock, 92.8 and 93.5 shares outstanding at March 31, 2013 and December 31, 2012, respectively19,800,00019,800,00018,900,000
Additional paid-in capital94,400,00094,400,0000
Retained earnings8,100,0008,100,0008,100,000
Accumulated other comprehensive income(8,836,200,000)(8,836,200,000)(10,581,700,000)
Total liabilities and shareholders' equity(153,700,000)(153,700,000)(493,200,000)
Stockholders' Equity Attributable to Parent8,785,000,0008,785,000,00010,096,600,000
Liabilities and Equity17,718,700,00017,718,700,00020,155,100,000
Net earnings189,100,000402,400,000 
Cash and cash equivalents1,930,600,0001,930,600,000320,600,000
Disposal Group, Including Discontinued Operation, Liabilities, Current$ 0$ 0$ 657,600,000
Adam H. Schechter
65535
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. It provides online and mobile applications to enable patients to check test results; and online applications for managed care organizations. It offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.